**Kymera Therapeutics, Inc. (KYMR)** shares rose by 16.6% to $116.46 in the last trading session, buoyed by high trading volume. This significant increase follows the company’s announcement of completing enrollment in the Phase IIb BROADEN2 study for its drug KT-621, aimed at treating moderate-to-severe atopic dermatitis, nearly six months ahead of schedule. The company expects to release topline data by the end of 2026, accelerating its timeline from mid-2027, which may lead to Phase III studies by mid-2027.
In addition, Kymera is projected to report a quarterly loss of $0.64 per share, a 32.6% year-over-year increase, with anticipated revenues of $38.13 million—up 232.1% compared to the same quarter last year.
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
